SP0080 Autoantibodies in Dermatomyositis

SP0080 Autoantibodies in Dermatomyositis

There are an increasing number of myositis-related autoantibodies found in adult and juvenile dermatomyositis (JDM) that identify distinct clinical profiles of disease, and may facilitate diagnosis and disease management. In JDM autoantibodies to MDA5, NXP2 and TIF1γ account for approximately 50% of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.21
1. Verfasser: McHugh, N.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 2
container_start_page 21
container_title Annals of the rheumatic diseases
container_volume 74
creator McHugh, N.
description There are an increasing number of myositis-related autoantibodies found in adult and juvenile dermatomyositis (JDM) that identify distinct clinical profiles of disease, and may facilitate diagnosis and disease management. In JDM autoantibodies to MDA5, NXP2 and TIF1γ account for approximately 50% of cases and identify different profiles of disease (e.g. anti-NXP2 and calcinosis). In adult-onset disease there are important additional risks such as between anti-TIF1γ and cancer and between anti-MDA5 and lung disease, and others such as anti-Mi2 are more common. The potential for using autoantibody levels to monitor disease activity and adjust therapy needs more exploration which will be possible when quantitative assays are more widely available.Disclosure of InterestNone declared
doi_str_mv 10.1136/annrheumdis-2015-eular.6601
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901795128</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322505955</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1278-5e89e6399f353b120d899336f3113b5c57a8aad2e3d955fae585bb83dbd74e153</originalsourceid><addsrcrecordid>eNqVkLFOwzAQhi0EEqXwDpW6IaX44tixxVQVCkiVQAJmy64d4aiJi50M3Vh4UZ4EhzCwMt3dr_-_O30IzQEvAAi7Um0b3mzfGBezHAPNbL9TYcEYhiM0gYLxJDN8jCYYY5IVgpWn6CzGOo2YA5-gy-en1OGvj89l33nVdk5742ycuXZ2Y0OjOt8cfHSdi-fopFK7aC9-6xS9rm9fVvfZ5vHuYbXcZBrykmfUcmEZEaIilCQJGy4EIawi6WVNt7RUXCmTW2IEpZWylFOtOTHalIUFSqZoPu7dB__e29jJ2vehTSclCAyloJDz5LoeXdvgYwy2kvvgGhUOErAc4Mg_cOQAR_7AkQOclGZjWjf1v4Lf69JvgQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901795128</pqid></control><display><type>article</type><title>SP0080 Autoantibodies in Dermatomyositis</title><source>BMJ Journals - NESLi2</source><creator>McHugh, N.</creator><creatorcontrib>McHugh, N.</creatorcontrib><description>There are an increasing number of myositis-related autoantibodies found in adult and juvenile dermatomyositis (JDM) that identify distinct clinical profiles of disease, and may facilitate diagnosis and disease management. In JDM autoantibodies to MDA5, NXP2 and TIF1γ account for approximately 50% of cases and identify different profiles of disease (e.g. anti-NXP2 and calcinosis). In adult-onset disease there are important additional risks such as between anti-TIF1γ and cancer and between anti-MDA5 and lung disease, and others such as anti-Mi2 are more common. The potential for using autoantibody levels to monitor disease activity and adjust therapy needs more exploration which will be possible when quantitative assays are more widely available.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.6601</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.21</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/21.4.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/21.4.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,777,781,3183,23552,27905,27906,77349,77380</link.rule.ids></links><search><creatorcontrib>McHugh, N.</creatorcontrib><title>SP0080 Autoantibodies in Dermatomyositis</title><title>Annals of the rheumatic diseases</title><description>There are an increasing number of myositis-related autoantibodies found in adult and juvenile dermatomyositis (JDM) that identify distinct clinical profiles of disease, and may facilitate diagnosis and disease management. In JDM autoantibodies to MDA5, NXP2 and TIF1γ account for approximately 50% of cases and identify different profiles of disease (e.g. anti-NXP2 and calcinosis). In adult-onset disease there are important additional risks such as between anti-TIF1γ and cancer and between anti-MDA5 and lung disease, and others such as anti-Mi2 are more common. The potential for using autoantibody levels to monitor disease activity and adjust therapy needs more exploration which will be possible when quantitative assays are more widely available.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkLFOwzAQhi0EEqXwDpW6IaX44tixxVQVCkiVQAJmy64d4aiJi50M3Vh4UZ4EhzCwMt3dr_-_O30IzQEvAAi7Um0b3mzfGBezHAPNbL9TYcEYhiM0gYLxJDN8jCYYY5IVgpWn6CzGOo2YA5-gy-en1OGvj89l33nVdk5742ycuXZ2Y0OjOt8cfHSdi-fopFK7aC9-6xS9rm9fVvfZ5vHuYbXcZBrykmfUcmEZEaIilCQJGy4EIawi6WVNt7RUXCmTW2IEpZWylFOtOTHalIUFSqZoPu7dB__e29jJ2vehTSclCAyloJDz5LoeXdvgYwy2kvvgGhUOErAc4Mg_cOQAR_7AkQOclGZjWjf1v4Lf69JvgQ</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>McHugh, N.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>SP0080 Autoantibodies in Dermatomyositis</title><author>McHugh, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1278-5e89e6399f353b120d899336f3113b5c57a8aad2e3d955fae585bb83dbd74e153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McHugh, N.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Family Health Database (Proquest)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McHugh, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SP0080 Autoantibodies in Dermatomyositis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>21</spage><pages>21-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>There are an increasing number of myositis-related autoantibodies found in adult and juvenile dermatomyositis (JDM) that identify distinct clinical profiles of disease, and may facilitate diagnosis and disease management. In JDM autoantibodies to MDA5, NXP2 and TIF1γ account for approximately 50% of cases and identify different profiles of disease (e.g. anti-NXP2 and calcinosis). In adult-onset disease there are important additional risks such as between anti-TIF1γ and cancer and between anti-MDA5 and lung disease, and others such as anti-Mi2 are more common. The potential for using autoantibody levels to monitor disease activity and adjust therapy needs more exploration which will be possible when quantitative assays are more widely available.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2015-eular.6601</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.21
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901795128
source BMJ Journals - NESLi2
title SP0080 Autoantibodies in Dermatomyositis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A36%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SP0080%E2%80%85Autoantibodies%20in%20Dermatomyositis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=McHugh,%20N.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=21&rft.pages=21-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.6601&rft_dat=%3Cproquest_cross%3E4322505955%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901795128&rft_id=info:pmid/&rfr_iscdi=true